Company environment · Sterile injectable quality · NMPA / CDE
A generic sterile injection under review in China
Under review; answering a formal deficiency notice. Start at the top to see what the company does, then the jobs AI models were given here and how each scored.
1What does this company do?
A generic drug company seeking approval in China for a sterile cancer-drug injection.
The injection is made by sterile filling into glass vials, which needs strict process, test and packaging evidence.
2Where is the product on its way to patients?
The application is under review, and China’s drug evaluation center has sent a deficiency notice.
- 1Discovery
- 2Lab & animal studies
- 3Human trials
- 4Filing & review
- The product is here
- 5Approved
- 6On the market
The regulator asks for tighter impurity and contamination limits, process-hold evidence, container-leak testing, and packaging-chemicals data.
3What is happening right now?
The deficiency notice has started an 80-day clock (desk date 30 September 2024).
Each job answers part of the notice from executed records, without inventing missing support.
4Which jobs were the models given?
4 jobs, each graded against a specialist’s checklist.
Scores are checks passed out of checks in the list. Each model ran each job once.
5–7Evidence, work and verdict
This company’s files stay private.
It is built from a real product’s records, so its files, runs and checklists aren’t published. To follow a job all the way down to each check, open one of the public environments.
Havenor Therapeutics (fictional, fully published) →
Broad Institute (real, public FDA record) →